Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Observational Study on Stelara Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)

Trial Profile

Prospective Observational Study on Stelara Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms PROSE
  • Sponsors Janssen-Cilag

Most Recent Events

  • 26 Jan 2021 Status changed from active, no longer recruiting to completed.
  • 05 Nov 2020 Planned End Date changed from 21 Nov 2021 to 29 Jan 2021.
  • 05 Nov 2020 Planned primary completion date changed from 30 Sep 2020 to 29 Jan 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top